Titre Tranexamic Acid During Cystectomy Trial (TACT)
Protocole ID TACT
ClinicalTrials.gov ID NCT01869413
Type(s) de cancer Vessie/urothélial
Phase Phase III
Type étude Traitement
Médicament Tranexamic acid
Institution CENTRE UNIVERSITAIRE DE SANTE MCGILL
   SITE GLEN
      1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville Montréal
Investigateur(trice) principal(e) Dr Wassim Kassouf
Coordonnateur(trice) Raphael Freitas
 514-934-1934 poste 36686
Statut Fermé
Critètes d'éligibilité
  • Participant ≥ 18 years at time of consent
  • Participant has bladder cancer and will undergo radical cystectomy to remove bladder
  • Participant is willing to receive blood products (i.e. packed red blood cells, platelets, plasma)
  • Have obtained Informed Consent
Critètes d'exclusion
  • Participant declines consent
  • Participants incapable (incompetent) of providing Informed Consent
  • Participant is under 18 years
  • Participant is unwilling to receive blood products due to personal reasons
  • Participant has ever had a pulmonary embolism, deep venous thrombosis, thrombotic stroke, atrial fibrillation, coronary stents or has active angina
  • Participant with known personal history of subarachnoid haemorrhage.
  • Participant has acquired disturbances to his / her colour vision (does not apply to congenital colour blindness)
  • Participant is pregnant (confirmed by βHCG test)
  • Participant has a known allergy to tranexamic acid